During the last few years a significant advance has been achieved in the understanding of the pathogenesis of inflammatory bowel disease (IBD). From twin studies it was evident that there is more that 50% concordance of Crohn’s disease (CD) in monozygotic twin pairs, however it is only 3.6% among dizygotic twins. These data indicate that the genetic background may be responsible for 50% of the risk or ‘susceptibility’ to develop CD. Obviously it is not a sufficient condition as otherwise there would be 100% concordance of disease in monozygotic twin pairs. Environmental factors as well must play an important role. This is further supported by the fact that there is only low development in genetic risk factors over ten thousands of years. In contrast, the incidence of CD and ulcerative colitis (UC) has dramatically increased in Western countries in the last 100 years. This further supports the concept of a ‘Western lifestyle factor(s)’ that triggers chronic intestinal inflammation in a genetically susceptible host. The proof of the concept of a genetic susceptibility was achieved in 2001 with the discovery that NOD2 is the most important susceptibility gene for CD. The function of NOD2 has been investigated in detail. NOD2 is an intracellular ‘alarm button’, a receptor recognizing invading bacteria that entered the mucosal wall. NOD2 mutants associated with susceptibility to CD seem to be deficient in their recognition of bacterial wall products. In a genome-wide association study a disease association was found in the autophagy-related 16-like 1 gene (ATG16L1). The ATG16L1 gene encodes a protein in the autophagosome pathway that processes intracellular bacteria. Based on these findings, CD is now discussed as an impaired and inadequate immune reaction to the gut bacteria which are a part of our environment (or perhaps ‘in-vironment’). In addition to NOD2 and ATG16L1, there are more ‘innate’ pathways by which commensal and pathogenic bacteria can directly interact with cells of the intestinal mucosa. The ‘environment concept’ and the ‘genetic concept’ of IBD pathophysiology are converging. With the finding that most susceptibility genes for CD and UC are involved in innate immune mechanisms and the primary defense against bacteria entering the mucosa, for the first time a unifying concept of the ‘genetic pathophysiology hypothesis’ and the ‘environment pathophysiology hypothesis’ of IBD was possible. Bacteria are the link between the environment and mucosal defense system.

Keywords:
Inflammatory bowel disease, Susceptibility genes, Crohnߣs disease, Environment, Pattern recognition receptors, Commensal bacteria, Gut flora
1.
Plomin R, Haworth CM, Davis OS: Common disorders are quantitative traits. Nat Rev Genet 2009;10:872–878.
2.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG: Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001;357:1925–1928.
3.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599–603.
4.
Cho JH: Update on the genetics of inflammatory bowel disease. Curr Gastroenterol Rep 2001;3:458–463.
5.
Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F: NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin Immunol 2010;134:251–261.
6.
Van Limbergen J, Wilson DC, Satsangi J: The genetics of Crohn’s disease. Annu Rev Genomics Hum Genet 2009;10:89–116.
7.
Fiocchi C: Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand? Dig Dis 2009;27:226–235.
8.
Melum E, Franke A, Karlsen TH: Genome-wide association studies – a summary for the clinical gastroenterologist. World J Gastroenterol 2009;15:5377–5396.
9.
Ruemmele FM: Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol 2010;26:332–336.
10.
Amre DK, Mack DR, Morgan K, Israel D, Deslandres C, Seidman EG, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Xhu Z, Grimard G, Levy E: Association between genome-wide association studies reported SNPs and pediatric-onset Crohn’s disease in Canadian children. Hum Genet 2010;128:131–135.
11.
Sanchez R, Levy E, Costea F, Sinnett D: IL-10 and TNF-α promoter haplotypes are associated with childhood Crohn’s disease location. World J Gastroenterol 2009;15:3776–3782.
12.
Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D, Silber G, Wrobel I, Quiros A, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Hakonarson H: Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009;41:1335–1340.
13.
Cooney R, Jewell D: The genetic basis of inflammatory bowel disease. Dig Dis 2009;27:428–442.
14.
Lees CW, Satsangi J: Genetics of inflammatory bowel disease: Implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009;3:513–534.
15.
Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Scholmerich J, Sartor RB: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277–2285.
16.
Rath HC, Wilson KH, Sartor RB: Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999;67:2969–2974.
17.
Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB: Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999;116:310–319.
18.
Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB: Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2-microglobulin transgenic rats. J Clin Invest 1996;98:945–953.
19.
Veltkamp C, Tonkonogy SL, De Jong YP, Albright C, Grenther WB, Balish E, Terhorst C, Sartor RB: Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(ε26) mice. Gastroenterology 2001;120:900–913.
20.
Moran JP, Walter J, Tannock GW, Tonkonogy SL, Sartor RB: Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice. Inflamm Bowel Dis 2009;15:1022–1031.
21.
Sartor RB: Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 2003;19:358–365.
22.
Schultz M, Tonkonogy SL, Sellon RK, Veltkamp C, Godfrey VL, Kwon J, Grenther WB, Balish E, Horak I, Sartor RB: IL-2-deficient mice raised under germ-free conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999;276:G1461–G1472.
23.
Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934–938.
24.
Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995;102:448–455.
25.
Swidsinski A, Loening-Baucke V, Bengmark S, Scholze J, Doerffel Y: Bacterial biofilm suppression with antibiotics for ulcerative and indeterminate colitis: consequences of aggressive treatment. Arch Med Res 2008;39:198–204.
26.
Swidsinski A, Loening-Baucke V, Theissig F, Engelhardt H, Bengmark S, Koch S, Lochs H, Dorffel Y: Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut 2007;56:343–350.
27.
Swidsinski A, Sydora BC, Doerffel Y, Loening-Baucke V, Vaneechoutte M, Lupicki M, Scholze J, Lochs H, Dieleman LA: Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis 2007;13:963–970.
28.
Canny G, Cario E, Lennartsson A, Gullberg U, Brennan C, Levy O, Colgan SP: Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am J Physiol Gastrointest Liver Physiol 2006;290:G557–G567.
29.
Canny G, Swidsinski A, McCormick BA: Interactions of intestinal epithelial cells with bacteria and immune cells: methods to characterize microflora and functional consequences. Methods Mol Biol 2006;341:17–35.
30.
Swidsinski A, Loening-Baucke V, Lochs H, Hale LP: Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 2005;11:1131–1140.
31.
Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005;43:3380–3389.
32.
Sydora BC, Martin SM, Lupicki M, Dieleman LA, Doyle J, Walker JW, Fedorak RN: Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. Inflamm Bowel Dis 2006;12:429–436.
33.
Perminow G, Beisner J, Koslowski M, Lyckander LG, Stange E, Vatn MH, Wehkamp J: Defective paneth cell-mediated host defense in pediatric ileal Crohn’s disease. Am J Gastroenterol 2010;105:452–459.
34.
Koslowski MJ, Beisner J, Stange EF, Wehkamp J: Innate antimicrobial host defense in small intestinal Crohn’s disease. Int J Med Microbiol 2010;300:34–40.
35.
Wehkamp J, Stange EF, Fellermann K: Defensin immunology in inflammatory bowel disease. Gastroenterol Clin Biol 2009;33 (suppl 3):S137–S144.
36.
Bevins CL, Stange EF, Wehkamp J: Decreased paneth cell defensin expression in ileal Crohn’s disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 2009;58:882–884.
37.
Wehkamp J, Stange EF: Is there a role for defensins in IBD? Inflamm Bowel Dis 2008;14(suppl 2):S85–S87.
38.
Gersemann M, Wehkamp J, Fellermann K, Stange EF: Crohn’s disease – defect in innate defence. World J Gastroenterol 2008;14:5499–5503.
39.
Nuding S, Fellermann K, Wehkamp J, Stange EF: Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut 2007;56:1240–1247.
40.
Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF: NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression. Gut 2004;53:1658–1664.
41.
Wehkamp J, Koslowski M, Wang G, Stange EF: Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol 2008;1(suppl 1):S67–S74.
42.
Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange EF, Bevins CL: Reduced paneth cell α-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA 2005;102:18129–18134.
43.
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF: A chromosome 8 gene-cluster polymorphism with low human β-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006;79:439–448.
44.
Kim YS, Min KS, Lee SI, Shin SJ, Shin KS, Kim EC: Effect of proinflammatory cytokines on the expression and regulation of human β-defensin 2 in human dental pulp cells. J Endod 2010;36:64–69.
45.
Barreau F, Madre C, Meinzer U, Berrebi D, Dussaillant M, Merlin F, Eckmann L, Karin M, Sterkers G, Bonacorsi S, Lesuffleur T, Hugot JP: NOD2 regulates the host response towards microflora by modulating t cell function and epithelial permeability in mouse Peyer’s patches. Gut 2010;59:207–217.
46.
Gariboldi S, Palazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L, Cavicchini S, Balsari A, Rumio C: Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of β-defensin 2 via TLR2 and TLR4. J Immunol 2008;181:2103–2110.
47.
Cosnes J: Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004;18:481–496.
48.
Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP: Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004;2:41–48.
49.
Cosnes J, Beaugerie L, Carbonnel F, Gendre JP: Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001;120:1093–1099.
50.
Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP: Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 1996;110:424–431.
51.
Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, Bar-Meir S, Chowers Y: Risk factors regarding the need for a second operation in patients with Crohn’s disease. Digestion 2005;72:248–253.
52.
Kane SV, Flicker M, Katz-Nelson F: Tobacco use is associated with accelerated clinical recurrence of Crohn’s disease after surgically induced remission. J Clin Gastroenterol 2005;39:32–35.
53.
Calkins BM: A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989;34:1841–1854.
54.
Mahid SS, Minor KS, Stevens PL, Galandiuk S: The role of smoking in Crohn’s disease as defined by clinical variables. Dig Dis Sci 2007;52:2897–2903.
55.
Cosnes J: Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis 2010;28:411–417.
56.
Johnson GJ, Cosnes J, Mansfield JC: Smoking cessation as primary therapy to modify the course of Crohn’s disease. Aliment Pharmacol Ther 2005;21:921–931.
57.
Lakatos PL, Szamosi T, Lakatos L: Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007;13:6134–6139.
58.
Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr: Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010;139:1147–1155.
59.
Cunningham MF, Docherty NG, Coffey JC, Burke JP, O’Connell PR: Postsurgical recurrence of ileal Crohn’s disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. World J Surg 2010;34:1615–1626.
60.
Dotan I: Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig Dis 2009;27:206–211.
61.
Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J: Does cigarette smoking influence the phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol 2007;102:577–588.
62.
Papi C, Festa V, Fagnani C, Stazi A, Antonelli G, Moretti A, Koch M, Capurso L: Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig Liver Dis 2005;37:247–253.
63.
Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J: Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552–557.
64.
Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP: The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213–1221.
65.
Yamamoto T: Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005;11:3971–3979.
66.
Yamamoto T, Keighley MR: Smoking and disease recurrence after operation for Crohn’s disease. Br J Surg 2000;87:398–404.
67.
Yamamoto T, Keighley MR: The association of cigarette smoking with a high risk of recurrence after ileocolonic resection for ileocecal Crohn’s disease. Surg Today 1999;29:579–580.
68.
Van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G: Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2009;15:1199–1207.
69.
Katschinski B, Logan RF, Edmond M, Langman MJ: Smoking and sugar intake are separate but interactive risk factors in Crohn’s disease. Gut 1988;29:1202–1206.
70.
Jarnerot G, Jarnmark I, Nilsson K: Consumption of refined sugar by patients with Crohn’s disease, ulcerative colitis, or irritable bowel syndrome. Scand J Gastroenterol 1983;18:999–1002.
71.
Silkoff K, Hallak A, Yegena L, Rozen P, Mayberry JF, Rhodes J, Newcombe RG: Consumption of refined carbohydrate by patients with Crohn’s disease in Tel-Aviv-Yafo. Postgrad Med J 1980;56:842–846.
72.
Thornton JR, Emmett PM, Heaton KW: Diet and Crohn’s disease: characteristics of the pre-illness diet. Br Med J 1979;2:762–764.
73.
Martini GA, Brandes JW: Increased consumption of refined carbohydrates in patients with Crohn’s disease. Klin Wochenschr 1976;54:367–371.
74.
Persson PG, Ahlbom A, Hellers G: Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992;3:47–52.
75.
Bartel G, Weiss I, Turetschek K, Schima W, Puspok A, Waldhoer T, Gasche C: Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis 2008;14:374–382.
76.
Gibson PR, Shepherd SJ: Personal view: food for thought – Western lifestyle and susceptibility to Crohn’s disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005;21:1399–1409.
77.
Ahuja V, Tandon RK: Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010;11:134–147.
78.
Yoshida Y, Murata Y: Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am 1990;74:67–90.
79.
Leong RW, Lau JY, Sung JJ: The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis 2004;10:646–651.
80.
Zheng JJ, Zhu XS, Huangfu Z, Shi XH, Guo ZR: Prevalence and incidence rates of Crohn’s disease in mainland china: a meta-analysis of 55 years of research. J Dig Dis 2010;11:161–166.
81.
Wang YF, Ouyang Q, Hu RW: Progression of inflammatory bowel disease in China. J Dig Dis 2010;11:76–82.
82.
Korzenik JR: Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol 2005;39:S59–65.
83.
Carbonnel F, Jantchou P, Monnet E, Cosnes J: Environmental risk factors in Crohn’s disease and ulcerative colitis: an update. Gastroenterol Clin Biol 2009;33(suppl 3):S145–157.
84.
Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP: Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut 1999;45:218–222.
85.
Danese S, Sans M, Fiocchi C: Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3:394–400.
86.
Wakefield AJ, Sawyerr AM, Hudson M, Dhillon AP, Pounder RE: Smoking, the oral contraceptive pill, and Crohn’s disease. Dig Dis Sci 1991;36:1147–1150.
87.
Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I: Prevalence and mechanism of non-steroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:196–202.
88.
Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ: Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4:203–211.
89.
Cámara RJ, Lukas PS, Begré S, Pittet V, von Känel R, Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) Group: Effects of social support on the clinical course of Crohn’s disease. Inflamm Bowel Dis 2010, Epub ahead of print.
90.
Levenstein S: Psychosocial factors in peptic ulcer and inflammatory bowel disease. J Consult Clin Psychol 2002;70:739–750.
91.
Prescott NJ, Dominy KM, Kubo M, Lewis CM, Fisher SA, Redon R, Huang N, Stranger BE, Blaszczyk K, Hudspith B, Parkes G, Hosono N, Yamazaki K, Onnie CM, Forbes A, Dermitzakis ET, Nakamura Y, Mansfield JC, Sanderson J, Hurles ME, Roberts RG, Mathew CG: Independent and population-specific association of risk variants at the IRGM locus with Crohn’s disease. Hum Mol Genet 2010;19:1828–1839.
92.
Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW: Virus-plus-susceptibility gene interaction determines Crohn’s disease gene ATG16L1 phenotypes in intestine. Cell 2010;141:1135–1145.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.